Ra Capital Management, L.P. Buys 124,893 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average price of $8.89 per share, with a total value of $1,110,298.77. Following the purchase, the director directly owned 16,763,043 shares of the company’s stock, valued at approximately $149,023,452.27. This trade represents a 0.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Trading Down 2.9%

Shares of Artiva Biotherapeutics stock traded down $0.27 during trading hours on Tuesday, reaching $8.91. The stock had a trading volume of 780,946 shares, compared to its average volume of 355,699. The firm has a 50 day simple moving average of $8.98 and a two-hundred day simple moving average of $6.20. The firm has a market capitalization of $220.26 million, a price-to-earnings ratio of -2.52 and a beta of 2.40. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Sell-side analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its position in shares of Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares in the last quarter. Prelude Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter worth $41,000. Dimensional Fund Advisors LP acquired a new position in shares of Artiva Biotherapeutics during the first quarter worth $131,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Artiva Biotherapeutics during the fourth quarter worth $91,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Artiva Biotherapeutics during the first quarter worth $139,000.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ARTV shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Wedbush lifted their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Finally, HC Wainwright lifted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Artiva Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.